既往存在NNRTI耐药相关突变的HIV感染者换用含多拉韦林方案后无病毒学失败
这项观察性研究纳入102例既往NNRTI病毒学失败且存在NNRTI耐药相关突变的HIV感染者,换用含多拉韦林方案后随访2年。第48周(0/87;0%)和第96周(0/86;0%)均无病毒学失败。
要点
- 102例既往NNRTI耐药相关突变者换用含多拉韦林方案,第48周病毒学失败0/87(0%)。
- 第96周病毒学失败0/86(0%),2年随访期间无病毒学失败发生。
- 25/102(25%)有记录的既往多拉韦林耐药相关突变,其中9/25(36%)为可能耐药,16/25(64%)为主要耐药。
核心结论
- 这是首个真实世界研究,为长期病毒学抑制且既往病毒携带特定NNRTI耐药相关突变的患者使用含多拉韦林方案提供了新见解。
研究设计与样本
- 观察性研究纳入2019年9月30日至2022年5月1日期间换用含多拉韦林方案、HIV-1 RNA≤50拷贝/mL且既往存在NNRTI耐药相关突变的HIV感染者,共分析102例。
主要发现
- 102例中男性63%,中位年龄59岁(IQR 51-63),HIV-1诊断后中位时间26年(IQR 16-31),抗逆转录病毒治疗中位时间22年(IQR 14-26),病毒学抑制中位时间7年(IQR 1-11)。
- 25/102(25%)有记录的既往多拉韦林耐药相关突变,其中9/25(36%)为可能耐药,16/25(64%)为主要耐药。
- 耐药谱主要为K103N、Y181C和/或G190A/E逆转录酶替换,占21/23。
- 距 last detection of NNRTI-RAMs 的中位时间为12年(IQR 5-17)。
- 2年随访期间无病毒学失败发生,第48周为0/87(0%),第96周为0/86(0%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Doravirine is licensed in patients living with HIV (PWH) harbouring no prior resistance to any NNRTIs. We aimed to evaluate in real life the efficacy of doravirine with prior NNRTI virological failure and NNRTI resistance-associated mutations (RAMs). METHODS: This observational study included PWH switched to a doravirine-containing regimen between 30 September 2019 and 1 May 2022, with an HIV-1 RNA of ≤50 copies/mL and past NNRTI-RAMs. The main outcome was the proportion of participants with virological failure at Week 48 and Week 96. Secondary outcomes evaluated the rate of viral suppression and transient virological blip, RAMs in the case of virological failure and side effects. RESULTS: A total of 102 patients were analysed, mostly men (63%), with a median age of 59 years (IQR 51-63). The median time since HIV-1 diagnosis was 26 years (IQR 16-31), on ART for 22 years (IQR 14-26) and virally suppressed for 7 years (IQR 1-11).Of the patients analysed, 25/102 (25%) had documented historical RAMs to doravirine, 9/25 (36%) showing possible resistance and 16/25 (64%) showing major resistance. The resistance profile primarily (21/23) consisted of the K103N, Y181C and/or G190A/E reverse transcriptase substitutions. Median time since the last detection of NNRTI-RAMs was 12 years (5-17). Over 2 years follow-up, no virological failure occurred, neither at Week 48 (0/87; 0%) nor Week 96 (0/86; 0%). CONCLUSIONS: This is the first real-world study to provide new insight about the use of doravirine-containing regimens as a treatment in long-term suppressed patients whose viruses harboured specific NNRTI-RAMs in their history.
引用
- Abdi B, Saliba S, Wirden M, et al. No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens. J Antimicrob Chemother. 2025. PMID: 39811907. doi:10.1093/jac/dkae481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。